logo

For the Inventor, By the Inventor

Gwynedd Valley, PA, United States of America

Edward L Engelhardt

This inventor holds 21 USPTO granted patents. Top assignee: Merck + Co., Inc.. Active years: 1976-1990.

USPTO Granted Patents = 21

% Patents Active = 100.0

Average Co-Inventor Count = 1.8

ph-index = 4

Forward Citations = 50(Granted Patents)


Company Filing History:

goldMedal21 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1976-1990

Loading Chart...
21 patents (USPTO):Explore Patents
1. 4897423 - Dinitrobenzenesulfonamides (1990-01-30),
2. 4853415 - 2-(substituted sulfamyl) derivatives of 4-nitrobenzamide as radiation (1989-08-01),
3. 4847294 - Derivatives of 2-(substituted sulfamyl)-6-nitrobenzoic acids, useful as (1989-07-11),
4. 4845284 - Substituted 3-nitrobenzenesulfonamides useful as adjuncts in radiation (1989-07-04),
5. 4731369 - Amides and esters of 2-(N-(hydroxypiperidinoalkyl) and (1988-03-15),
6. 4694020 - Derivatives of 2-(substituted sulfamyl)-6-nitrobenzoic acids and (1987-09-15),
7. 4647588 - 2-(substituted sulfamyl)-6-nitrobenzoic acid amides and pharmaceutical (1987-03-03),
8. 4619927 - Novel nitropyrazinyl- and nitropyridinyl- substituted piperazin-3-one (1986-10-28),
9. 4603133 - Amides and esters of 2-[N-(morpholinoalkyl)aminosulfonyl]-6-nitrobenzoic (1986-07-29),
10. 4271187 - Substituted phenyl alanine antihypertensive agents (1981-06-02),
11. 4258211 - 4-Aminoaliphatic-2,3,5,6-[dibenzobicyclo[5.1.0]octanes] and salts thereof (1981-03-24),
12. 4206216 - Antihypertensive N-heterocyclicalanines (1980-06-03),
13. 4153715 - Indolyl amino acids useful as antihypertensive agents (1979-05-08),
14. 4071570 - Arylperfluoroalkanes (1978-01-31),
15. 4065572 - Amino acids and esters thereof useful as antihypertensive agents (1977-12-27),

Title: Edward L. Engelhardt: Innovator in Pharmaceutical Compounds

Introduction

Edward L. Engelhardt, a prolific inventor based in Gwynedd Valley, PA, has made significant contributions to the field of pharmaceuticals. With a remarkable record of 21 patents, Engelhardt has dedicated his career to developing innovative solutions that enhance medical treatment, particularly in oncology.

Latest Patents

Among Engelhardt's latest patents are the groundbreaking inventions related to Dinitrobenzenesulfonamides. These compounds are characterized by a specific formula wherein "n" can be an integer of 2, 3, 4, or 5, and "R₁" can be either hydrogen or an alkyl group. Additionally, he has developed 2-(substituted sulfamyl) derivatives of 4-nitrobenzamide, which are proven to increase the sensitivity of hypoxic cancer cells to x-rays and gamma radiation. His patents detail methods for preparing these compounds, protocols for administering them to both human patients and animals, as well as the pharmaceutical compositions containing them.

Career Highlights

Edward L. Engelhardt has built an impressive career at Merck & Company, Inc., where his innovative research and development efforts contribute to the company's mission of improving healthcare solutions. Engelhardt’s focus on creating compounds that target cancer cell sensitization demonstrates his commitment to advancing medical treatments.

Collaborations

Throughout his career, Engelhardt has collaborated with fellow innovators such as Walfred S. Saari and Joseph G. Atkinson. These partnerships have enabled the sharing of knowledge, expertise, and resources, further enhancing their contributions to pharmaceutical innovations.

Conclusion

Edward L. Engelhardt's work exemplifies the power of innovation in the pharmaceutical industry. With his extensive portfolio of patents and impactful collaborations, he continues to play a vital role in developing therapies that have the potential to revolutionize cancer treatment and improve patient outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…